Magnetic Nanomaterials: Revolutionizing Biomedical Diagnostics and Treatment

Magnetic nanomaterials (MNPs), especially iron-oxide–based
superparamagnetic nanoparticles (SPIONs), have advanced
biomedical diagnostics and therapeutics by enabling highly sensitive
point-of-care assays, MRI contrast enhancement, magnetically
guided drug delivery and magnetic hyperthermia. Quantitative
advances include: up to ~40-fold improvement in limit-of-detection
(LOD) for lateral-flow immunoassays when using aggregated
magnetic labels versus single particles, and attomolar-level nucleic
acid detection reported in magnetically-enhanced lateral-flow
formats.
Magnetic hyperthermia studies report observable
temperature rises of ~5 °C/min under select AMF conditions and
SAR/SLP (specific absorption rate / specific loss power) values that vary widely (typically <10 to a few hundred W·g⁻ ¹, depending on
particle composition, size, and field parameters). MNPs (e.g.,
ferumoxytol) are under active investigation as safer alternatives to
some gadolinium agents for MRI, showing promising T₁ /T₂ contrast
performance in low-field systems. These numerical improvements
result from optimized cores (doping, multicore “nanoflowers”),
controlled surface coatings for stability and targeting, and assay/field
engineering (magnetic control, reader sensitivity). Key challenges
remain: in vivo biodistribution and clearance, reproducible SAR
measurement under clinically-relevant AMF limits (H·f safety
product), large-scale reproducible synthesis, and regulatory
translation. This paper presents a structured review and an original
consolidated exposition (introduction, materials, methodology,
discussion, quantitative conclusions), two summary tables, two
schematic figures, a list of abbreviations, five keywords, and ten APA
style references with inline citations to the primary literature to
support quantitative claims.